Eli Lil­ly throws down the gaunt­let in obe­si­ty race, chal­leng­ing No­vo Nordisk with new PhI­II read­out

No­vo Nordisk made waves ear­ly last year af­ter show­ing that its block­buster di­a­betes drug was al­so high­ly ef­fec­tive at treat­ing non-di­a­bet­ic adults with obe­si­ty. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER